Guardant Health disclosed the $59 million upfront acquisition of MetaSight Diagnostics and offered ambitious 2026 screening guidance tied to its Shield colorectal cancer screening test. Management said Shield volumes and revenues should ramp sequentially across 2026, forecasting screening revenue of $162–$174 million and 210,000–225,000 tests, excluding potential upside from guideline inclusion or Quest Diagnostics partnership. Guardant is positioning the MetaSight technology to broaden its screening portfolio while integrating Shield into Quest’s ordering platform to expand clinical reach. The company’s financial commentary paired near‑term commercialization execution plans with continued investment in screening sales and medical infrastructure.